Small drug vial with MMR vaccine

Small drug vial with MMR vaccine. (© Leigh Prather - stock.adobe.com)

In a nutshell

  • At current vaccination rates, measles could become endemic in the US again within 21 years, with researchers projecting 851,000 cases over 25 years.
  • If vaccination rates decline by 50%, the US could see over 51 million measles cases, 9.9 million rubella cases, and 4.3 million polio cases over 25 years, resulting in more than 159,000 deaths.
  • Increasing vaccination rates by just 5% would prevent measles from becoming endemic again and reduce cases to only 5,800 over 25 years.

STANFORD, Calif. — America faces a brewing public health threat as vaccination rates continue to slide downward. Diseases once eliminated through widespread immunization could stage a comeback, with measles likely to lead the charge.

A new investigation published in JAMA reveals that measles could become endemic in the U.S. again within 21 years if current vaccination trends persist. The consequences would worsen dramatically if rates drop further, potentially affecting millions of Americans with diseases many have never seen firsthand.

Most parents today have never witnessed a child with measles, let alone polio or diphtheria — a fact that, according to co-author Dr. Nathan Lo, contributes to “a general fatigue with vaccines” and growing “distrust and misinformation about vaccine effectiveness and safety.”

The Hidden Cost of Vaccine Hesitancy

The research team used computer modeling to project what happens under various vaccination scenarios for four diseases: measles, rubella, polio, and diphtheria. Their findings paint a concerning picture.

Under current vaccination rates, which vary between 88% and 96% across states, measles would likely reestablish itself within two decades, causing approximately 851,000 cases over 25 years.

A 10% decline in vaccination rates would dramatically increase this number to 11.1 million cases. Should rates drop by 50%, the model predicts more than 51 million measles cases over 25 years – affecting roughly 15% of the entire U.S. population.

These aren’t just numbers on a page. They represent actual suffering: permanent brain damage, birth defects in babies whose mothers contract rubella during pregnancy, paralysis from polio, and tens of thousands of preventable deaths.

The study concluded that “measles [is] likely to be the first to return to endemic levels and may occur even under current vaccination levels without improved vaccine coverage,” with its spread driven by lower immunization rates in certain states.

The threat is already materializing. A recent outbreak in western Texas infected more than 620 people, leading to 64 hospitalizations and the deaths of two children.

Child with measles rash on body
Scientists say measles is the disease most likely to make a widespread comeback in the U.S.. (© bilanol – stock.adobe.com)

Regional Differences Create Vulnerability Hotspots

The research uncovered significant regional variations in disease vulnerability. Texas faces particularly high risk for measles outbreaks due to its combination of lower vaccination rates, large population, and international travel connections.

“Massachusetts has high vaccination rates and was consistently low risk. Both California and Texas were higher risk, even after accounting for larger population size, because vaccination rates in both have dropped and there’s a lot of travel to those states,” Kiang noted in a statement.

This patchwork of protection creates weak points where outbreaks can begin and spread, even when overall national vaccination rates appear adequate.

The timing of these findings coincides with growing political debate about childhood vaccination requirements. Some proposals include removing certain vaccines from the recommended schedule or eliminating school vaccine mandates altogether – moves that would accelerate the decline in coverage.

A Path Forward

Despite the concerning projections, the research offers hope. Boosting measles vaccination by just 5% would prevent its return to endemic status and slash the 25-year case count to about 5,800 – a 99% reduction compared to what would happen with a 10% decline.

“With measles, we’re right on the cusp. Increasing vaccination levels by just 5% brings the number of measles cases down, safely away from returning to endemic levels,” Dr. Lo explained. “These are the kinds of small percentages that can really be a tipping point. It’s empowering that a small segment of the population can make a difference here.”

After generations protected by vaccination, Americans now have the luxury of focusing on extremely rare vaccine side effects rather than the diseases themselves. But that equation changes dramatically when diseases return.

“It’s worth emphasizing that there really shouldn’t be any cases at this point, because these diseases are preventable,” Kiang added. “Anything above zero is tragic. When you’re talking about potentially thousands or millions, that’s unfathomable.”

The message from researchers is clear: societies that forget their public health history risk repeating it. Vaccines don’t just protect individuals – they maintain a barrier that keeps dangerous diseases at bay. As that barrier weakens, the diseases remain poised to rush back in.

Paper Summary

Methodology

The researchers developed a simulation model to estimate the impact of declining vaccination rates for measles, rubella, polio, and diphtheria across all 50 U.S. states and Washington, D.C. They used a stochastic, discrete time, age-specific, individual-based model that simulated infection importation and dynamic transmission for each disease. The model incorporated state-specific data on demographics, population immunity levels (based on vaccination coverage data from 2004-2023), and infection importation risk. It ran for a 25-year period under various scenarios, including current vaccination levels, decreases of 5% to 100% in vaccination coverage, and increases of 5% to 10%. The model tracked cases, complications (including neurological sequelae, congenital rubella syndrome, paralytic polio, hospitalizations, and deaths), and whether diseases returned to endemic status (defined as when the national effective reproduction number remained at or above 1 for a 12-month period).

Results

At current vaccination levels, the model predicted approximately 851,300 measles cases over 25 years, with an 83% probability that measles would become endemic again (in about 21 years). Smaller numbers of rubella (190), polio (18), and diphtheria (8) cases were predicted. With a 5% increase in vaccination, measles cases would drop to 5,800 and would not return to endemic status. With a 10% decrease in vaccination, measles cases jumped to 11.1 million. Under a 50% decline scenario, the model predicted 51.2 million measles cases, 9.9 million rubella cases, 4.3 million polio cases, and 197 diphtheria cases over 25 years. This would result in 51,200 cases of postmeasles neurological damage, 10,700 cases of congenital rubella syndrome, 5,400 cases of paralytic polio, 10.3 million hospitalizations, and 159,200 deaths. Measles would become endemic within 5 years under this scenario, rubella in 18 years, and polio in about 20 years (in 56% of simulations).

Limitations

The model used simplified assumptions about disease transmission, immunity, social mixing, and demographics. It didn’t account for within-state heterogeneity in vaccination coverage, which could lead to larger outbreaks than predicted. The model didn’t include spillover of outbreaks between states, potentially underestimating total cases. It didn’t account for potential increases in vaccination that might occur in response to outbreaks or significant public health interventions. The infection importation rates were based on historical estimates and may not perfectly reflect future risks. The model also didn’t account for age-specific differences in complication outcomes and included both symptomatic and subclinical infections in case estimates.

Funding and Disclosures

Dr. Kiang reported receiving grants from the National Institutes of Health for unrelated work. Dr. Maldonado reported receiving grants from and serving on data and safety monitor boards for Pfizer. Dr. Hotez reported being a coinventor on non-revenue-generating patents for neglected tropical diseases and on a COVID-19 recombinant protein vaccine technology, with various licensing arrangements. Dr. Lo reported receiving personal fees from the World Health Organization for unrelated work.

Publication Information

The study, titled “Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US,” was published online in JAMA on April 24, 2025. The authors are Mathew V. Kiang, Kate M. Bubar, Yvonne Maldonado, Peter J. Hotez, and Nathan C. Lo, from Stanford University, Baylor College of Medicine, and Texas A&M University.

About StudyFinds Staff

StudyFinds sets out to find new research that speaks to mass audiences — without all the scientific jargon. The stories we publish are digestible, summarized versions of research that are intended to inform the reader as well as stir civil, educated debate. StudyFinds Staff articles are AI assisted, but always thoroughly reviewed and edited by a Study Finds staff member. Read our AI Policy for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

Sophia Naughton

Associate Editor

Leave a Reply